USFDA issues zero observation to Lupin Vizag facility

Mumbai: Global pharma major Lupin Limited has announced that the United States Food and Drug Administration (U.S. FDA) has completed a Pre-Approval and GMP Inspection of its API manufacturing facility located in Visakhapatnam (Vizag), India with no observations.

The inspection was conducted from March 6 to March 10, 2023.

“We are pleased with the successful completion of the inspection at our Vizag facility,” said Nilesh Gupta, Managing Director, Lupin. “This accomplishment is a testament to our commitment to upholding global quality standards across all our manufacturing sites, and to provide quality affordable healthcare for all.”

Read also: Lupin unveils schizophrenia drug Lurasidone Hydrochloride in US